BETWEEN SCYLLA AND CHARYBDIS: NAVIGATING THE STRAITS OF CLINICAL TRIALS FROM DRUG DISCOVERY TO DRUG APPROVAL

Pyruvate Dehydrogenase Complex (PDC)

Net reaction:
Pyruvate + NAD⁺ + CoASH → Acetyl-CoA + NADH⁺ + H⁺ + CO₂

Peter W. Stacpoole, PhD, MD
Professor of Medicine,
Division of Endocrinology, Diabetes & Metabolism,
Professor of Biochemistry and Molecular Biology
pws@ufl.edu
Pathways and Cofactors Involved in Mitochondrial Energetics

**Glycolysis**
- Glucose → Pyruvate → Lactate

**Cytosol**
- Alanine
- Pyruvate
- Lactate

**Mitochondrion**
- Pyruvate → Acetyl CoA → Oxaloacetate → Citrate

**TCA Cycle**
- α-Ketoglutarate → Succinyl CoA → Oxaloacetate

**β-Oxidation**
- Long Chain Fatty Acyl CoA → L.C.F. Acyl CoA → Acetyl CoA

**Pathway - Orange**
- Carnitine palmitoyl transferase 1 → Carnitine palmitoyl transferase 2

**Vitamin or Cofactor - Green**
- Biotin (B7)
- Niacin (B3)
- Riboflavin
- Folic acid
- Pantothenate (B5)
- B12

**Enzyme function - Blue**
- Thiamine (B1) TPP
- Niacin (B3) redox rxn
- Pantothenate (B5) CoA synthesis
- Biotin (B7) Propionyl CoA carboxylase
- Cobalamin (B12) Methylmalonyl CoA mutase
- Niacin (B3) Redox rxn
- Riboflavin (B2) Redox rxn
- Pantothenate (B5) CoA synthesis

**Respiratory Chain**
- Redox transport
- Electron transport
- Heme synthesis

**Energy Is Life!**
Loss of function mutations in any component

- E1α subunit mutations > 80% of cases with molecular genetic cause

Age of clinical onset usually < 1 yr

Commonest clinical signs and symptoms:
- Developmental delay (cognitive and milestones)
- Hypotonia
- Seizures

Commonest cause of congenital lactic acidosis (CLA)
- ↑ blood and/or CSF lactate
- L/P ≤ 20

Brain imaging
- Enlarged ventricles
- Brain atrophy
- Other structural abnormalities
- Leigh syndrome (bilaterally symmetric degeneration of basal ganglia, brain stem, cerebellum)

Most patients die within months—a few years of diagnosis but a few with mild mutations live into adulthood
- CLA in neonatal period portends dire prognosis

WHAT IS A RARE DISEASE?

- In U.S., frequency of ≤ 200,000
  - Defined by Congress in 1983 (Orphan Products Act)
- 5,000-6,000 diseases qualify
- ~12 M Americans affected
- Historically fell into “Valley of Death”

Potential New Rx ➔ Licensing, Testing, Approval ➔ $
A POSSIBLE THERAPY—VINEGAR WITH A KICK!

- Dichloroacetate (DCA)
- Investigational drug (mg/kg/d)
  - Genetic mitochondrial diseases
  - Others
- Ubiquitous in biosphere (µg/kg/d)
  - TCE metabolite
  - Disinfection by-product
- Fog and rain

10,000 fold conc. range
HOW DCA WORKS

Glucose $\xrightarrow{\text{Glycolysis}}$ Mitochondrial Membrane

Pyruvate $\rightarrow$ Pyruvate + NAD$^+$ + CoASH

$\xrightarrow{\text{PDC}}$ AcetylCoA + NADH + H$^+$ + CO$_2$

$\xrightarrow{\text{PDP}}$ PO$_4$

$\xrightarrow{\text{PDK}}$ PO$_4$

$\xrightarrow{\text{PDC-PO}_4}$ PO$_4$

TCA Cycle $\rightarrow$ ATP

Respiratory Chain

$\frac{1}{2}O_2 \rightarrow H_2O$
PRELIMINARY FINDINGS — HOPE AND DISPAIR

- Diverse anecdotal evidence of benefit
- Alexander and Mom
- Next step: a clinical trial
WHAT IS A “CLINICAL TRIAL”? 

- An experiment in which the test subjects are humans. 
- Prospective, not retrospective. 
- Often involves a novel intervention or a novel use of an established intervention (drug, vaccine, gene, food, device). 
- Investigational New Drug (IND) permit held by sponsor or investigator. 
- Investigators include physicians, nurses, dieticians, laboratory technicians, biostatisticians. 
- Common venues for rare disease trials are Academic Health Centers.

There are no FDA-approved therapies for any primary mitochondrial disease.
PHASES OF A CLINICAL TRIAL

- **Phase I:** Drug metabolism and dose-ranging studies in healthy volunteers.
- **Phase II:** Blinded or open-label studies in the target population for safety and efficacy.
- **Phase III:** Randomized, double-blind, placebo-controlled study in target population for safety and efficacy.
NEW DRUG APPLICATION (NDA)

- Submitted to Food and Drug Administration (FDA).
- Requires one or more pivotal Phase III trials.
- Foreign studies may help, or not.
SAFEGUARDS AND OMBUDSMEN

- Institutional Review Board (IRB)
- Data Safety Monitoring Board (DSMB)
- FDA
2006: FIRST RCT IN CLA

- 43 children (5.6 yr at entry)
- PDCD (11); RC +/- mtDNA mutation (32)

Depicted are means ± SD of venous blood lactate levels obtained 1 hour after the meal was consumed.

The ratio of the proportions of concordant, discordant, and tied pairs of Global Assessment of Treatment Efficacy (GATE) ratings were used to calculate the GOR point estimates and 95% confidence intervals (CIs) for each major outcome variable. Where the 95% CI includes the value of 1, no significant difference in treatment versus placebo group was observed.

Is survival in PDC improved?

Effect of DCA on blood and CSF lactate concentrations. The red lines denote mean changes. Data from open label and controlled trials.

Kaplan-Meier plot of percentage of survival of 36 subjects.

**BETWEEN A ROCK AND A HARD PLACE**

- Scylla
  - Non-patentable molecule, so Pharma uninterested
  - 1\textsuperscript{st} trial showed no obvious clinical benefit

- Charybdis
  - Rare disease research tough to do and fund and tougher to do clinical trials
  - Greener pastures elsewhere?
The design of the trial is:

1. Four years duration, recruiting at least 24 children (1 m – 18 y)
2. Placebo-controlled
3. Double-blind
4. Crossover, followed by open label phase
   a. Each patient is own control
   b. All patients receive DCA
5. Randomized (flip of a coin)
6. Mainly parental/guardian home assessments, using novel survey tool
OBSERVER REPORTED OUTCOME (OBSRO) MEASURE

- Major effort by PDCD organization and FDA
- Prospectively evaluates how patient feels and functions at home
- Stipulated by FDA as Primary Efficacy Outcome measure, the results of which may led to drug approval
- Novel tool for mitochondrial diseases
- Daily assessment of multiple domains (e.g., Motor, Neurological, GI, General Health)
- Uploaded daily by recorder to Data Coordinating Center (DCC) for data management and analysis
- Patient clinic visits (~5) over ~10 month crossover period, then visits every 6 months during open label phase (months-years)
POTENTIAL OBSTACLES AND LIMITATIONS

- Recognition of conflict within rare disease professional community about RCTs
- Funding problems can delay trial and discourage investigators
- Single center study can limit FDA enthusiasm
- Eligible patients can be lost to logistics of travel and to competing trials
- Small population requires large and effective catchment net
- Consensus on diagnostic criteria, frustrating, humbling and educational
- Importance of choosing validated assessment tools
- Questionable applicability of key outcome measures (if available)
Evaluation of DCA in PDCD promising
Multicenter study possible
PDCD organization and collaborating centers
Medosome Biotec interested in commercializing DCA genotyping kit
WE NEED YOUR HELP!

1. Advocate!
   - Families
   - Caregivers
   - UMDF: see PDCD Landing page at www.umdf.org/pdcd
   - Donors

2. Participate!
   - Phase 3 trial

3. Benefit!
   - DCA is/is not safe and effective therapy
   - If FDA-approved, could be covered by insurance
   - Pioneering the first approved Rx for any primary (congenital) mitochondrial disease
ENERGY IS LIFE!

PDC as therapeutic target for:
1. Diabetes
2. Heart disease
3. Pulmonary dis.
4. Cancer
5. Others?

Pathways and Cofactors Involved in Mitochondrial Energetics

- Glucose to Long Chain Fatty Acyl CoAs
- Pyruvate to Acetyl CoA
- Oxaloacetate to Citrate
- Succinyl CoA to α-Ketoglutarate
- α-KG dehydrogenase

- Glycolysis
- Long Chain Fatty Acyl CoAs
- Camitine palmitoyl transferanse 1
- Camitine palmitoyl transferanse 2
- Camitine

- β-Oxidation

- TCA Cycle
- Respiratory Chain
- Electron transport
- ATP synthesis
- Heme synthesis

- Pathway - Orange
- Vitamin or Cofactor - Green
- Enzyme function - Blue
THANK YOU!

Questions?
Comments?